Literature DB >> 16713590

Enhanced accumulation of tau in doubly transgenic mice expressing mutant betaAPP and presenilin-1.

Eriko Samura1, Mikio Shoji, Takeshi Kawarabayashi, Atsushi Sasaki, Etsuro Matsubara, Tetsuro Murakami, Xu Wuhua, Shuta Tamura, Masaki Ikeda, Koich Ishiguro, Takaomi C Saido, David Westaway, Peter St George Hyslop, Yasuo Harigaya, Koji Abe.   

Abstract

Abeta amyloidosis and tauopathy are characteristic changes in the brain of Alzheimer's disease. Although much evidence suggests that Abeta deposit is a critical initiation factor, the pathological pathway between Abeta amyloidosis and tau accumulation remains unclear. Tau accumulation was examined in the doubly transgenic mouse (APP-PS) expressing betaAPP(KM670/671NL) (Tg2576) and presenilin-1 L286V (PS-1 L286Vtg). Accelerated and enhanced Abeta amyloid deposits were detected from 8 weeks. Tau accumulation appeared at 4.5 months and markedly increased in dystrophic neurites around Abeta amyloid. Accumulated tau was phosphorylated, conformationally altered, and argyrophilic. Expression of tau and accumulation of sarkosyl-insoluble phosphorylated tau were increased in APP-PS brains compared with those of Tg2576 mice. Straight or twisted tubules mimicking paired helical filament were revealed at electron microscopic level in 16-month-old APP-PS. These findings suggest that mutant presenilin-1 accelerated Abeta-induced tauopathy and further promoted fibril formation of tau.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16713590     DOI: 10.1016/j.brainres.2005.12.134

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  11 in total

1.  The γ-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer's disease.

Authors:  Annamaria Lanzillotta; Ilenia Sarnico; Marina Benarese; Caterina Branca; Cristina Baiguera; Birgit Hutter-Paier; Manfred Windisch; Pierfranco Spano; Bruno Pietro Imbimbo; Marina Pizzi
Journal:  J Mol Neurosci       Date:  2010-12-22       Impact factor: 3.444

2.  Discovery and structure activity relationship of small molecule inhibitors of toxic β-amyloid-42 fibril formation.

Authors:  Heiko Kroth; Annalisa Ansaloni; Yvan Varisco; Asad Jan; Nampally Sreenivasachary; Nasrollah Rezaei-Ghaleh; Valérie Giriens; Sophie Lohmann; María Pilar López-Deber; Oskar Adolfsson; Maria Pihlgren; Paolo Paganetti; Wolfgang Froestl; Luitgard Nagel-Steger; Dieter Willbold; Thomas Schrader; Markus Zweckstetter; Andrea Pfeifer; Hilal A Lashuel; Andreas Muhs
Journal:  J Biol Chem       Date:  2012-08-13       Impact factor: 5.157

3.  Alzheimer's disease: ageing-related or age-related? New hypotheses from an old debate.

Authors:  Orso Bugiani
Journal:  Neurol Sci       Date:  2011-05-13       Impact factor: 3.307

4.  Genetic ablation of luteinizing hormone receptor improves the amyloid pathology in a mouse model of Alzheimer disease.

Authors:  Jing Lin; Xian Li; Fangping Yuan; Ling Lin; Christine L Cook; Ch V Rao; Zhenmin Lei
Journal:  J Neuropathol Exp Neurol       Date:  2010-03       Impact factor: 3.685

5.  Abeta40 inhibits amyloid deposition in vivo.

Authors:  Jungsu Kim; Luisa Onstead; Suzanne Randle; Robert Price; Lisa Smithson; Craig Zwizinski; Dennis W Dickson; Todd Golde; Eileen McGowan
Journal:  J Neurosci       Date:  2007-01-17       Impact factor: 6.167

Review 6.  Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice.

Authors:  Donna M Wilcock; Carol A Colton
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-03       Impact factor: 4.388

Review 7.  Presenilin 1 Regulates Membrane Homeostatic Pathways that are Dysregulated in Alzheimer's Disease.

Authors:  Carol A Deaton; Gail V W Johnson
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

8.  Ultrastructural studies in APP/PS1 mice expressing human ApoE isoforms: implications for Alzheimer's disease.

Authors:  Krikor Dikranian; Jungsu Kim; Floy R Stewart; Marilyn A Levy; David M Holtzman
Journal:  Int J Clin Exp Pathol       Date:  2012-07-29

9.  Correlation of pyroglutamate amyloid β and ptau Ser202/Thr205 levels in Alzheimer's disease and related murine models.

Authors:  Joerg Neddens; Magdalena Daurer; Stefanie Flunkert; Kerstin Beutl; Tina Loeffler; Lauren Walker; Johannes Attems; Birgit Hutter-Paier
Journal:  PLoS One       Date:  2020-07-09       Impact factor: 3.240

Review 10.  Visual and Ocular Manifestations of Alzheimer's Disease and Their Use as Biomarkers for Diagnosis and Progression.

Authors:  Fatimah Zara Javaid; Jonathan Brenton; Li Guo; Maria F Cordeiro
Journal:  Front Neurol       Date:  2016-04-19       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.